Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population

Experimental and Clinical Transplantation

Volumn 8, Issue 1, 2010, Pages 14-18

  Maharaj, Suman ^a   Assounga, Alain Guy ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Estimated glomerular filtration rate; Kidney transplant; mTOR inhibitor

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GUM HYPERTROPHY; HUMAN; HYPERTROPHY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MEDICAL AUDIT; MEDICAL RECORD REVIEW; NEPHROTOXICITY; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PROTEIN URINE LEVEL; PROTEINURIA; SOUTH AFRICA; TREATMENT OUTCOME;

CLINICAL AUDIT; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; PROTEINURIA; RETROSPECTIVE STUDIES; SIROLIMUS; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME;

EID: 77749309852     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant. 2005;20:2517-2523.
2. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004;4:1869-1875.
3. Kreis H, Cisterne JM, Walter L, et al. Sirolimus in association with MMF induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation. 2000;69:1252-1260.
4. Groth CG, Backman L,Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67:1036-1042.
5. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant. 2006;21:488-493.
6. Iaria G, Pisani F, Lorio B, et al. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression. Transplant Proc. 2006; 38:1018-1019.
7. Joles J A, Van Goor H, Van Der Horst MLC, Van Tol A, Elema JD, Koomans HA. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats. Lab Invest. 1995;73:912-921.
8. Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62(5):1743-1749.
9. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant. 2004;17:215-220.
10. Smith K, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol. 2003;14:1037-1045.
11. Lieberthal W, Fuhro R, Andry C, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol. 2001;281:F693-F706.
12. Schwartz GJ, Kwong T, Erway B, et al. Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. Pediatr Nephrol. 2009;24:113-119.
13. Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant. 2005,5:1306-1311.
14. Graziani MS, Gambaro G, Mantovani L, et al. Diagnostic accuracy of a reagent strip for assessing urinary albumin excretion in the general population. Nephrol Dial Transplant. 2009,24:1490-1494.
15. Kahan BD. Two-year results ofmulticentre phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc. 2003;35(suppl 3):37S-51S
16. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation. 2003;75:157-160.
17. Ryffel B, Weber E, Mihatsch MJ. Nephrotoxicity of immunosuppressants in rats: comparison of macrolides with ciclosporin. Exp Nephrol. 1994;2:324-333.
18. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8 year experience. Transplant Proc. 2003;35(suppl 31):52s-57s.
19. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233-242.